Foreign investor interest in the South Korean biopharma sector appears to be strong or even growing, despite the recent domestic political turmoil.
Recent activity has included direct foreign VC investment in a Korean venture, R&D incubation programs involving multinationals and a planned IPO in Korea by a foreign biotech.
Among the key strengths highlighted by foreign investors are the country's discovery capabilities, world-class research, government support, open mindset and talent pool.
But some still see a tendency for Korean companies to out-license early on and limited management diversity.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

Multiple Active Investments And Financings